Carfilzomib
VIDEO: Considerations to help develop personalized treatment plans for myeloma patients
VIDEO: Monoclonal antibodies, CAR-T and more for multiple myeloma treatment
VIDEO: Incorporating important multiple myeloma trial results into practice
VIDEO: Preliminary IsKia trial results promising in multiple myeloma subgroup
Healio spoke with Chakra Chaulagain, MD, about preliminary phase 3 results from the IsKia trial presented at ASH Annual Meeting and Exposition.
VIDEO: Studies on early-relapse multiple myeloma treatment highlighted at ASH
NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses noteworthy research on early-relapse multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.
Elotuzumab-based quadruplet produces durable responses in newly diagnosed multiple myeloma
A quadruplet regimen comprising the monoclonal antibody elotuzumab plus weekly carfilzomib, lenalidomide and dexamethasone conferred a 72% 3-year PFS rate among patients with newly diagnosed multiple myeloma, phase 2 trial results showed.
Regimen provides ‘unprecedented’ PFS benefit in relapsed multiple myeloma
The addition of isatuximab-irfc to carfilzomib and dexamethasone conferred a durable PFS benefit to patients with relapsed multiple myeloma, according to updated results of the randomized phase 3 IKEMA trial.
Spotlight on multiple myeloma: New drug approvals highlight treatment advances
Myeloma Awareness Month is observed in March.
FDA approves Kyprolis regimen for relapsed or refractory multiple myeloma
The FDA approved a combination of carfilzomib, a subcutaneous formulation of daratumumab, and dexamethasone for certain patients with relapsed or refractory multiple myeloma.
CAR T-cell therapy, bispecific T-cell engagers, other exciting treatments in multiple myeloma
Maung Myo Htut, MD, associate clinical professor in the division of multiple myeloma within the department of hematology and hematopietic cell transplantation at City of Hope, discussed treatment developments in multiple myeloma, including exciting data from ASH 2020, the role of CAR T-cell therapy, autologous hematopoietic stem cell transplant, consolidation therapy and more.